WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test
ANAHEIM, Calif., Oct. 21, 2014 /PRNewswire/ -- Influenza will affect as many as 200,000 people this year and with flu-associated deaths in the United States as high as 49,000 people. The main way that influenza viruses are thought to spread is from person to person in respiratory droplets of coughs and sneezes.
Ebola has a serve way of death, but kills much fewer people each year than the Flu. The transmission of Ebola is also done by human fluids including sweat, saliva, blood and other bodily fluids. The Ebola virus can spread fast with improper testing or slow testing. As with the flu, both diseases need to be caught early to give the best results in treatment.
WholeHealth Products' Rapid Influenza Combination Test detects both Influenza A and Influenza B at the same time.
The Influenza A Test is a visual and rapid assay for the presumptive qualitative detection of influenza Type A antigens from nasal washes and aspirates. The influenza B Test utilizes monoclonal antibodies against Influenza Type B viral nucleoproteins. The test begins with a extraction of Type B nucleoproteins. Extracted specimens are then added to the test device. If type B nucleoproteins are present, they bind to the antibody-gold conjugate in the test membrane and form a complex. This complex migrates across the membrane and is captured by type B antibody in the membrane.
The test takes only 15 minutes.
This test is for professional use only.
Inspired by its slogan, "Love Life Live Long," WholeHealth Products is committed to building long term relationships with the medical and healthcare professional and the patients, helping saves lives.
WholeHealth Products is your partner in the "Business of Science".
Headquartered in Anaheim, California, WholeHealth Products. (OTC: GWPC) is a diversified company. WholeHealth Products' has a line of more 20 professional diagnostic tests for hospitals, doctors, clinics and healthcare centers.
Certain information set forth in this fact sheet may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of WholeHealth Products Inc, including, but not limited to, risks associated with the impact of general economic conditions, industry conditions, dependence upon regulatory approvals, and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
Photo - http://photos.prnewswire.com/prnh/20141021/153472
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wholehealth-products-is-proud-to-be-releasing-its-influenza-a-and-b-combo-test-on-the-heels-of-the-announcing-of-its-phase-2-completion-of-the-rapid-ebola-test-413346645.html
SOURCE WholeHealth Products Inc.
Share this article